Kiniksa’s Mavrilimumab Fails In Late-Stage COVID-19 Trial, Doubles Back On Arcalyst
The firm’s anti GM-CSF candidate has underwhelmed in a study in hospitalized COVID-19 patients, triggering renewed focus on its recently launched product Arcalyst for recurrent pericarditis.
You may also be interested in...
Keeping Track: US FDA Approves J&J’s Novel MS Drug Ponvory, Breakthrough Pericarditis Claim For Kiniksa’s Arcalyst
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
The Irish firm’s cannabis-derived nabiximols spray missed the primary endpoint in a late-stage multiple sclerosis spasticity trial, but it is unfazed as hopes remain for two ongoing spasticity studies.